DIQTA 1.0: Drug-Induced QT Prolongation Atlas

ARIPIPRAZOLE LAUROXIL

Classification:Moderate-DIQT concern

Severity Score:2.0

OVERDOSAGE
Human Experience
Common adverse reactions (reported in at least 5% of all overdose cases) reported with oral aripiprazole overdosage (alone or in combination with other substances) include vomiting, somnolence, and tremor. Other clinically important signs and symptoms observed in one or more patients with aripiprazole overdoses (alone or with other substances) include acidosis, aggression, aspartate aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional state, convulsion, blood creatine phosphokinase increased, depressed level of consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration, respiratory arrest, status epilepticus, and tachycardia.
ADVERSE REACTIONS
Clinical Studies Experience
Investigations: weight decreased, hepatic enzyme increased, blood glucose increased, blood lactate dehydrogenase increased, gamma glutamyl transferase increased, blood prolactin increased, blood urea increased, blood creatinine increased, blood bilirubin increased, electrocardiogram QT prolonged, glycosylated hemoglobin increased

Current Drug

Other Drugs

QT Prolongation

307

23785

Other ADRs

154354

38227233

Odds Ratio = 3.197

ATC Code(s):

Active Ingredient:aripiprazole lauroxil

Active Ingredient UNII:B786J7A343

Drugbank ID:DB14185

PubChem Compound:N/ADIR Classification

CAS Number:1259305-29-7

Dosage Form(s):injection, suspension, extended release

Route(s) Of Administrator:intramuscular

Daily Dose:

Chemical Structure:

SMILE Code:
CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12

N/A